# Quality Assurance Report

---

# Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0218 |
| Population Package | PP-0218 |
| Title | RECIST-based Assessment |
| Version | 1.0.0 |
| Review Status | PASS |
| QA Date | 2026-08-09 |

---

# 1. QA Executive Summary

PP-0218 was produced only after the Decision Batch was explicitly **Approved + Locked**.

The production was checked against:

- locked PP-0218 Decision Batch;
- CORE_WORKING_RULES;
- Gold Population Package Specification;
- approved Discussion Gold reference;
- PP Registry;
- supplied PP-0058 and PP-0059 Gold packages;
- ESMO-ASCO 2023 response-evaluation material;
- adjacent PP ownership.

The four required Gold artifacts are present:

- `01_CKO.md`
- `02_KNOWLEDGE_PASSPORT.md`
- `03_PRIMARY_EVIDENCE_PACKAGE.md`
- `04_QA_REPORT.md`

---

# 2. Layer 1 — Content QA

| Criterion | Result |
|---|---|
| Single clinical educational question | PASS |
| Scope respected | PASS |
| Full approved decision coverage | PASS |
| Internal consistency | PASS |
| Logical organization | PASS |
| Knowledge blocks complete | PASS |
| Patient-facing interpretation present | PASS |
| Technical application layer clearly defined | PASS |

---

# 3. Atomicity QA

## Core Question

> **How is a RECIST-based assessment constructed from measurable disease, target lesions, non-target disease and new lesions to produce an overall response assessment?**

**PASS**

The package is neither:

- a generic RECIST introduction;
- a generic RECIST 1.1 introduction;
- a response-assessment package;
- an imaging package.

It owns the integrated RECIST application layer.

---

# 4. Layer 2 — Clinical QA

## 4.1 RECIST purpose

**PASS**

RECIST is presented as a standardized response-assessment framework, particularly relevant to clinical-trial endpoint harmonization.

ESMO-ASCO directly supports this framing. fileciteturn19file0

---

## 4.2 Appropriate setting

**PASS**

The package does not imply that RECIST applies identically to every cancer situation.

---

## 4.3 Measurable / non-measurable disease

**PASS**

Both are included and their different roles in overall assessment are preserved.

---

## 4.4 Target lesions

**PASS**

The package includes:

- target-lesion concept;
- maximum five total;
- maximum two per organ;
- standardized measurement role.

This is directly supported by ESMO-ASCO. fileciteturn19file0

---

## 4.5 Sum of diameters

**PASS**

The package explains the role of the sum of longest diameters in longitudinal assessment.

---

## 4.6 Nadir

**PASS**

The package distinguishes baseline from nadir and explains its role at high clinical depth without creating a redundant standalone mathematical algorithm.

---

## 4.7 Non-target disease

**PASS**

The package explicitly prevents target-lesion-only interpretation.

---

## 4.8 New lesions

**PASS**

New lesions are treated as a separate and clinically important component of progression assessment.

---

## 4.9 Lymph nodes

**PASS**

Special RECIST lymph-node considerations are included without turning PP-0218 into a radiology manual.

---

## 4.10 CR / PR / SD / PD

**PASS**

The categories are included as integrated outputs.

Detailed standalone ownership remains with PP-0063–0066.

---

## 4.11 Progression

**PASS**

Progression is explained as an integrated RECIST outcome rather than simple subjective tumor enlargement.

The longitudinal principle that RECIST PD remains PD once established is preserved. fileciteturn19file0

---

## 4.12 Response confirmation

**PASS**

Confirmation is explicitly framed as context-dependent and particularly relevant to selected single-arm trial settings.

No universal “every response must be confirmed” rule was introduced. fileciteturn19file0

---

## 4.13 Measurement error

**PASS**

Measurement uncertainty is explicitly integrated.

ESMO-ASCO identifies measurement error as a core RECIST competency. fileciteturn19file0

---

## 4.14 iRECIST

**PASS**

iRECIST is included only as an interface.

The full iRECIST algorithm and pseudo-progression rules remain delegated.

---

# 5. Layer 3 — Adjacent Package Overlap QA

## PP-0058 — RECIST

**PASS**

PP-0058 remains the definition/concept package.

PP-0218 uses its concepts without reproducing the foundational package.

PP-0058 explicitly excludes technical criteria. fileciteturn19file15

---

## PP-0059 — RECIST 1.1

**PASS**

PP-0059 remains the conceptual RECIST 1.1 package.

PP-0218 owns the applied technical assessment layer.

PP-0059 explicitly excludes target lesions, measurable disease, response categories, sum of diameters and iRECIST. fileciteturn19file5

---

## PP-0060–0067

**PASS**

The package integrates the component concepts without replacing their individual educational ownership.

---

## PP-0217 — Response Assessment

**PASS**

PP-0217 owns clinical meaning of treatment response.

PP-0218 owns how the RECIST-based classification is constructed.

---

## PP-0219 — Post-treatment Imaging

**PASS**

PP-0219 retains ownership of imaging methodology.

PP-0218 only uses imaging-derived information as input to RECIST assessment.

---

## PP-0220–0223

**PASS**

Surveillance, recurrence and recurrent/metastatic management remain downstream.

---

# 6. Layer 4 — Evidence QA

## Direct source

**ESMO-ASCO 2023**

**PASS**

The source directly supports the major technical RECIST concepts used in PP-0218. fileciteturn19file0

---

## Supporting package sources

PP-0058 and PP-0059 were reviewed for architectural continuity.

**PASS**

Their explicit exclusions support the downstream ownership of PP-0218. fileciteturn19file15turn19file5

---

## Registry

**PASS**

PP Registry confirms PP-0217 → PP-0218 → PP-0219 ownership sequence. fileciteturn19file3

---

# 7. Layer 5 — Educational QA

| Criterion | Result |
|---|---|
| Patient-facing language | PASS |
| Technical terminology explained | PASS |
| Technical depth appropriate to topic | PASS |
| Misconceptions addressed | PASS |
| Clinical safety preserved | PASS |
| Difference between RECIST and treatment decision clear | PASS |
| Difference between RECIST and staging clear | PASS |
| Difference between RECIST and pathology response clear | PASS |
| Difference between RECIST and surveillance clear | PASS |

---

# 8. Misconception QA

The package explicitly addresses:

- RECIST does not measure every lesion.
- Target lesions are not simply the five largest tumors.
- Non-target disease still matters.
- Shrinkage alone does not guarantee response.
- SD is not meaningless.
- PD is not an automatic treatment-stop order.
- RECIST is not staging.
- CR is not synonymous with cure.
- RECIST and iRECIST are not interchangeable.
- Small measurement changes may reflect uncertainty.

**PASS**

---

# 9. Clinical Safety Review

| Safety Item | Result |
|---|---|
| No individualized treatment prescription | PASS |
| No dosing recommendation | PASS |
| No automatic treatment change from RECIST result | PASS |
| No claim that PD means no further treatment | PASS |
| No claim that CR means cure | PASS |
| No substitution of RECIST for clinical judgment | PASS |
| No full iRECIST algorithm | PASS |
| No detailed imaging protocol | PASS |
| No individualized prognosis | PASS |

---

# 10. Governance QA

| Criterion | Result |
|---|---|
| Correct PP identity | PASS |
| User-controlled PP execution | PASS |
| Approved + Locked decision honored | PASS |
| Gold structure preserved | PASS |
| Four required artifacts produced | PASS |
| Source-first evidence workflow preserved | PASS |
| Boundary declared | PASS |
| Adjacent PP ownership preserved | PASS |
| Knowledge Graph included | PASS |
| Evidence traceability included | PASS |
| QA depth preserved | PASS |

---

# 11. Gold Depth Integrity Review

## Absolute Gold Depth Rule

The package must not be:

- shortened;
- compacted;
- summarized;
- made shallower than approved Gold references;
- reduced in evidence traceability;
- reduced in Knowledge Graph depth;
- reduced in QA depth;
- reduced in patient-facing depth.

## Result

**PASS**

The package includes:

- 23 clinical knowledge blocks;
- educational objectives;
- explicit scope;
- technical application architecture;
- misconceptions;
- key messages;
- patient questions;
- Knowledge Graph;
- boundary;
- evidence hierarchy;
- evidence matrix;
- detailed evidence notes;
- evidence limitations;
- evidence gaps;
- source traceability;
- delegation matrix;
- layered QA;
- safety review.

The package is intentionally more technically substantive than PP-0058/0059 because PP-0218 owns the downstream applied RECIST layer.

---

# 12. Cross-artifact Consistency

| Domain | CKO | KP | EP | QA | Status |
|---|---:|---:|---:|---:|---|
| PP identity | ✓ | ✓ | ✓ | ✓ | PASS |
| Clinical question | ✓ | ✓ | ✓ | ✓ | PASS |
| Scope | ✓ | ✓ | ✓ | ✓ | PASS |
| Target lesions | ✓ | ✓ | ✓ | ✓ | PASS |
| Measurable disease | ✓ | ✓ | ✓ | ✓ | PASS |
| Non-target disease | ✓ | ✓ | ✓ | ✓ | PASS |
| Sum of diameters | ✓ | ✓ | ✓ | ✓ | PASS |
| New lesions | ✓ | ✓ | ✓ | ✓ | PASS |
| Lymph nodes | ✓ | ✓ | ✓ | ✓ | PASS |
| CR/PR/SD/PD | ✓ | ✓ | ✓ | ✓ | PASS |
| Measurement error | ✓ | ✓ | ✓ | ✓ | PASS |
| Response confirmation | ✓ | ✓ | ✓ | ✓ | PASS |
| iRECIST interface | ✓ | ✓ | ✓ | ✓ | PASS |
| Clinical decision boundary | ✓ | ✓ | ✓ | ✓ | PASS |
| Knowledge Graph | ✓ | ✓ | ✓ | ✓ | PASS |
| Boundary | ✓ | ✓ | ✓ | ✓ | PASS |
| Evidence traceability | ✓ | ✓ | ✓ | ✓ | PASS |
| QA | ✓ | ✓ | ✓ | ✓ | PASS |

---

# 13. Boundary Integrity

**Core =** Application of RECIST 1.1 to create an integrated response assessment.

**Supporting =** Foundational RECIST concepts, imaging interface, gastric-cancer context and iRECIST interface.

**Explicitly Excluded =** Detailed imaging methodology, full iRECIST, treatment decisions, prognosis, pathology response, surveillance and recurrence detection.

**Delegated-to PP =** PP-0058/0059; PP-0060–0068; PP-0217; PP-0219–0223; PP-0231–0232 and any dedicated iRECIST package established by the authoritative Project Coordinator sequence.

**PASS**

Boundary is clean, ownership-oriented and non-duplicative.

---

# 14. Source-First Integrity

**PASS**

PP-specific materials were searched before production.

The key direct source was the supplied ESMO-ASCO 2023 RECIST curriculum.

PP-0058, PP-0059 and PP Registry were used to establish continuity and boundary.

No unsupported general medical knowledge was used to silently replace the project source architecture.

---

# 15. Knowledge Graph Integrity

**PASS**

The graph correctly establishes:

```text
RECIST
  ↓
RECIST 1.1
  ↓
RECIST component packages
  ↓
PP-0217 Response Assessment
  ↓
PP-0218 RECIST-based Assessment
  ↓
PP-0219 Post-treatment Imaging
  ↓
Surveillance / Recurrence
```

The immunotherapy branch is represented through an iRECIST interface without absorbing the full specialized framework.

---

# 16. Final QA Decision

## Content QA

**PASS**

## Clinical QA

**PASS**

## Evidence QA

**PASS**

## Educational QA

**PASS**

## Governance QA

**PASS**

## Clinical Safety

**PASS**

## Adjacent PP Overlap

**PASS**

## Source-First Integrity

**PASS**

## Gold Depth Integrity

**PASS**

## Cross-artifact Consistency

**PASS**

## Boundary Integrity

**PASS**

## Package Integrity

**PASS**

---

# Final Status

# PASS — GOLD — READY FOR INTEGRATION

PP-0218 is confirmed as the **applied RECIST assessment layer** between the foundational RECIST packages and clinical/post-treatment imaging packages, with explicit preservation of the approved scope and adjacent-package ownership.
